Site-specific genome engineering of primary human natural killer cells for programmable anti-tumor function
Authors:
- Vincent AllainVAVincent Allain
- Allison G. RothrockARAllison G. Rothrock
- Pierre-Louis BernardPBPierre-Louis Bernard
- William A. NybergWNWilliam A. Nyberg
- Alexis TalbotATAlexis Talbot
- Joseph J. MuldoonJMJoseph J. Muldoon
- Jing-Yi ChungJCJing-Yi Chung
- Angela ToATAngela To
- Christopher R. ChangCCChristopher R. Chang
- Gabriella R. KimmerlyGKGabriella R. Kimmerly
- Chang LiuCLChang Liu
- Tasha TsaoTTTasha Tsao
Preprint
Abstract
Natural killer (NK) cells are emerging as a promising platform for engineered adoptive cell therapies. However, gene editing in NK cells remains challenging, and more effective strategies are needed. Here, we established a robust, feeder-free, and modular workflow for genome engineering in primary human NK cells, combining CRISPR/Cas9 with AAV6-mediated transgene delivery. Efficient site-specific transgene integration was achieved at various loci and can be coupled with concurrent disruption of the target locus in a single editing step. Furthermore, transgene expression was tunable according to the integration site and promoter. We applied this strategy to target a chimeric antigen receptor (CAR) transgene to a panel of inhibitory NK receptor loci, establishing a synergistic approach to enhance anti-tumor activity and facilitate the reliable comparison of CAR variants without expression bias. We identified TIGIT as an ideal locus that supports strong CAR expression and anti-tumor function. This genome engineering framework, which leverages multiple, complementary and precisely controlled genetic edits, can support the rational design of future NK-cell therapies tailored to overcome cell-intrinsic limitations and tumor-specific barriers.Keywords
Funding Information
- DRC Center Grant NIH P30 (DK063720)
- UCSF Medical Scientist Training Program (T32GM141323)
- NCI F99/K00 Fellowship (K00CA245718)
This publication has 103 references indexed in Scilit:
- An iPSC-derived CD19/BCMA CAR-NK therapy in a patient with systemic sclerosisCell, 2025
- Enhancing anti-tumor immunity of natural killer cells through targeting IL-15R signalingCancer Cell, 2025
- CD38-CAR human NK cells in combination with ATRA enhance cytotoxicity against CD38-expressing hematologic malignanciesBlood Neoplasia, 2024
- An evolved AAV variant enables efficient genetic engineering of murine T cellsCell, 2023
- Engineering the next generation of CAR-NK immunotherapiesInternational Journal of Hematology, 2021
- Targeted delivery of CRISPR-Cas9 and transgenes enables complex immune cell engineeringCell Reports, 2021
- Drug target validation in primary human natural killer cells using CRISPR RNPJournal of Leukocyte Biology, 2020
- Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK CellsCell, 2018
- Characterization of three loci for homologous gene targeting and transgene expressionBiotechnology and Bioengineering, 2013
- Induction of Antigen-Specific Tumor Immunity by Genetic and Cellular Vaccines against MAGE: Enhanced Tumor Protection by Coexpression of Granulocyte-Macrophage Colony-Stimulating Factor and B7-1Molecular Medicine, 1996